sc13dza
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D/A
Amendment #3
Under the Securities Exchange Act of 1934
Eden Bioscience Corporation
(Name of Issuer)
COMMON STOCK, $.0025 par value
(Title of Class of Securities)
Tamara R. Wagman
124 E. 4th Street
Tulsa, Oklahoma 74103
(918) 583-9922
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
July 11, 2007
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition
that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e),
240.13d-1(f) or 240.13d-1(g), check the following box. o
Note: Schedules filed in paper format shall include a signed original and five copies of the
schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on
this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for
the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to
the liabilities of that section of the Act but shall be subject to all other provisions of the Act
(however, see the Notes).
| |
|
|
|
|
|
|
|
|
|
|
CUSIP No. |
|
279445886 |
SCHEDULE 13D |
| |
|
|
|
|
|
| 1 |
|
NAMES OF REPORTING PERSONS:
Value Fund Advisors, LLC |
| | |
| |
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):
|
| |
|
| |
|
|
| 2 |
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):
|
| |
(a) o |
| |
(b) o |
| |
|
|
| 3 |
|
SEC USE ONLY: |
| |
|
| |
|
| |
|
|
| 4 |
|
SOURCE OF FUNDS (SEE INSTRUCTIONS): |
| |
|
| |
See Item 3 |
| |
|
|
| 5 |
|
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e): |
| |
|
| |
o |
| |
|
|
| 6 |
|
CITIZENSHIP OR PLACE OF ORGANIZATION: |
| |
|
| |
Oklahoma
|
| |
|
|
|
| |
7 |
|
SOLE VOTING POWER: |
| |
|
|
| NUMBER OF |
|
1,058,903 |
| |
|
|
|
| SHARES |
8 |
|
SHARED VOTING POWER: |
| BENEFICIALLY |
|
|
| OWNED BY |
|
-0- |
| |
|
|
|
| EACH |
9 |
|
SOLE DISPOSITIVE POWER: |
| REPORTING |
|
|
| PERSON |
|
1,058,903 |
| |
|
|
|
| WITH |
10 |
|
SHARED DISPOSITIVE POWER: |
| |
|
|
| |
|
-0- |
| |
|
|
| 11 |
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: |
| |
|
| |
1,058,903 |
| |
|
|
| 12 |
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS): |
| |
|
| |
o
|
| |
|
|
| 13 |
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11): |
| |
|
| |
13% |
| |
|
|
| 14 |
|
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS): |
| |
|
| |
OO (Limited Liability Company) |
| |
|
|
|
|
|
|
|
|
|
|
CUSIP No. |
|
279445886 |
SCHEDULE 13D |
| |
|
|
|
|
|
| 1 |
|
NAMES OF REPORTING PERSONS:
Boston Avenue Capital, LLC |
| | |
| |
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):
|
| |
|
| |
|
|
| 2 |
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):
|
| |
(a) o |
| |
(b) o |
| |
|
|
| 3 |
|
SEC USE ONLY: |
| |
|
| |
|
| |
|
|
| 4 |
|
SOURCE OF FUNDS (SEE INSTRUCTIONS): |
| |
|
| |
See Item 3 |
| |
|
|
| 5 |
|
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e): |
| |
|
| |
o |
| |
|
|
| 6 |
|
CITIZENSHIP OR PLACE OF ORGANIZATION: |
| |
|
| |
Oklahoma
|
| |
|
|
|
| |
7 |
|
SOLE VOTING POWER: |
| |
|
|
| NUMBER OF |
|
1,058,903 |
| |
|
|
|
| SHARES |
8 |
|
SHARED VOTING POWER: |
| BENEFICIALLY |
|
|
| OWNED BY |
|
-0- |
| |
|
|
|
| EACH |
9 |
|
SOLE DISPOSITIVE POWER: |
| REPORTING |
|
|
| PERSON |
|
1,058,903 |
| |
|
|
|
| WITH |
10 |
|
SHARED DISPOSITIVE POWER: |
| |
|
|
| |
|
-0- |
| |
|
|
| 11 |
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: |
| |
|
| |
1,058,903 |
| |
|
|
| 12 |
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS): |
| |
|
| |
o
|
| |
|
|
| 13 |
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11): |
| |
|
| |
13% |
| |
|
|
| 14 |
|
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS): |
| |
|
| |
OO (Limited Liability Company) |
| |
|
|
|
|
|
|
|
|
|
|
CUSIP No. |
|
279445886 |
SCHEDULE 13D |
| |
|
|
|
|
|
| 1 |
|
NAMES OF REPORTING PERSONS:
Yorktown Avenue Capital, LLC |
| | |
| |
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):
|
| |
|
| |
|
|
| 2 |
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):
|
| |
(a) o |
| |
(b) o |
| |
|
|
| 3 |
|
SEC USE ONLY: |
| |
|
| |
|
| |
|
|
| 4 |
|
SOURCE OF FUNDS (SEE INSTRUCTIONS): |
| |
|
| |
See Item 3 |
| |
|
|
| 5 |
|
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e): |
| |
|
| |
o |
| |
|
|
| 6 |
|
CITIZENSHIP OR PLACE OF ORGANIZATION: |
| |
|
| |
Oklahoma
|
| |
|
|
|
| |
7 |
|
SOLE VOTING POWER: |
| |
|
|
| NUMBER OF |
|
1,058,903 |
| |
|
|
|
| SHARES |
8 |
|
SHARED VOTING POWER: |
| BENEFICIALLY |
|
|
| OWNED BY |
|
-0- |
| |
|
|
|
| EACH |
9 |
|
SOLE DISPOSITIVE POWER: |
| REPORTING |
|
|
| PERSON |
|
1,058,903 |
| |
|
|
|
| WITH |
10 |
|
SHARED DISPOSITIVE POWER: |
| |
|
|
| |
|
-0- |
| |
|
|
| 11 |
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: |
| |
|
| |
1,058,903 |
| |
|
|
| 12 |
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS): |
| |
|
| |
o
|
| |
|
|
| 13 |
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11): |
| |
|
| |
13% |
| |
|
|
| 14 |
|
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS): |
| |
|
| |
OO (Limited Liability Company) |
| |
|
|
|
|
|
|
|
|
|
|
CUSIP No. |
|
279445886 |
SCHEDULE 13D |
| |
|
|
|
|
|
| 1 |
|
NAMES OF REPORTING PERSONS:
Charles M. Gillman |
| | |
| |
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):
|
| |
|
| |
|
|
| 2 |
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):
|
| |
(a) o |
| |
(b) o |
| |
|
|
| 3 |
|
SEC USE ONLY: |
| |
|
| |
|
| |
|
|
| 4 |
|
SOURCE OF FUNDS (SEE INSTRUCTIONS): |
| |
|
| |
See Item 3 |
| |
|
|
| 5 |
|
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e): |
| |
|
| |
o |
| |
|
|
| 6 |
|
CITIZENSHIP OR PLACE OF ORGANIZATION: |
| |
|
| |
United States of America
|
| |
|
|
|
| |
7 |
|
SOLE VOTING POWER: |
| |
|
|
| NUMBER OF |
|
1,058,903 |
| |
|
|
|
| SHARES |
8 |
|
SHARED VOTING POWER: |
| BENEFICIALLY |
|
|
| OWNED BY |
|
-0- |
| |
|
|
|
| EACH |
9 |
|
SOLE DISPOSITIVE POWER: |
| REPORTING |
|
|
| PERSON |
|
1,058,903 |
| |
|
|
|
| WITH |
10 |
|
SHARED DISPOSITIVE POWER: |
| |
|
|
| |
|
-0- |
| |
|
|
| 11 |
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: |
| |
|
| |
1,058,903 |
| |
|
|
| 12 |
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS): |
| |
|
| |
o
|
| |
|
|
| 13 |
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11): |
| |
|
| |
13% |
| |
|
|
| 14 |
|
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS): |
| |
|
| |
IN |
| |
|
|
|
|
|
|
|
|
|
|
CUSIP NO. |
|
279445886 |
SCHEDULE 13D |
Item 1. Security and Issuer
This Schedule 13D relates to shares of Common Stock, $.0025 par value (the “Common Stock”) of Eden
Bioscience Corporation, a Washington corporation (the “Issuer”). The principal executive office and
mailing address of the Issuer is 11816 North Creek Parkway N., Bothell, Washington 98011.
Item 2. Identity and Background
This Schedule 13D is jointly filed by Value Fund Advisors, LLC (“VFA”), Boston Avenue Capital, LLC
(“Boston”), Yorktown Avenue Capital, LLC (“Yorktown”), and Charles M. Gillman (“Gillman”) (the
“Reporting Persons”). VFA is the general manager of Boston and Yorktown. Gillman is the manager of
VFA.
The principal business office address for each of the Reporting Persons is 415 South Boston, 9th
Floor, Tulsa, Oklahoma 74103.
The principal business of Boston and Yorktown is business investment. The principal business of VFA
is investment management. The principal occupation of Gillman is managing various investment
entities.
None of the entities or persons identified in this Item 2 has, during the past five years, been
convicted of any criminal proceeding (excluding traffic violations or similar misdemeanors), nor
been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction
and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining
future violations of, or prohibiting or mandating activities subject to, federal or state
securities laws or finding any violation with respect to such laws.
VFA, Boston and Yorktown are organized under the laws of the State of Oklahoma. Gillman is a U.S.
citizen.
Item 3. Source and Amount of Funds or Other Consideration
As of July 27, 2007, Boston and Yorktown had invested $899,333 (including commissions and fees) in
the Common Stock. The source of these funds was the working capital of Boston and Yorktown.
Item 4. Purpose of Transaction
The purpose of the acquisition of the Common Stock is for investment, and the acquisitions of the
Common Stock were made in the ordinary course of business and were not made for the purpose of
acquiring control of the Issuer.
Although no Reporting Person has any specific plan or proposal to acquire or dispose of the Common
Stock, consistent with its investment purpose, each Reporting Person at any time and from time to
time may acquire additional Common Stock or dispose of any or all of its Common Stock depending
upon an ongoing evaluation of the investment in the Common Stock, prevailing market conditions,
other investment opportunities, liquidity requirements of the Reporting Persons, and/or other
investment considerations.
Also, consistent with the investment purpose, the Reporting Persons may
engage in communications with one or more shareholders of the Issuer, one or more officers of the
Issuer and/or one or more members of the board of
| |
|
|
|
|
|
|
|
|
|
|
CUSIP NO. |
|
279445886 |
SCHEDULE 13D |
directors of the Issuer and/or one or more
representatives of the Issuer regarding the Issuer, including but not limited to its operations.
The Reporting Persons may discuss ideas that, if effected may result in any of the following: the
acquisition by persons of additional Common Stock of the Issuer, an extraordinary corporate
transaction involving the Issuer, and/or changes in the board of directors or management of the
Issuer.
Except to the extent the foregoing may be deemed a plan or proposal, none of the Reporting Persons
has any plans or proposals which relate to, or could result in, any of the matters referred to in
paragraphs (a) through (j), inclusive, of the instructions to Item 4 of Schedule 13D. The Reporting
Persons may, at any time and from time to time, review or reconsider their position and/or change
their purpose and/or formulate plans or proposals with respect thereto.
Item 5. Interest in Securities of the Issuer
(a) and (b) According to the Issuer’s latest Form 10-Q filed May 11, 2007, there were 8,149,554
shares of Common Stock issued and outstanding as of May 1, 2007. Based on such information, after
taking into account the transactions described in Item 5(c) below, Boston directly owns 272,633
shares of Common Stock (approximately 3.3%) and Yorktown directly owns 786,270 shares of Common
Stock (approximately 9.7%) of the Issuer. VFA, as general manager of Boston and Yorktown, and
Gillman, as manager of VFA, may also be deemed to beneficially own the 1,058,903 shares of Common
Stock (approximately 13%) of the Issuer held by Boston and Yorktown.
As the manager of VFA, which serves as general manager to Boston and Yorktown, Gillman has sole
voting and investment power of the Common Stock held by Boston and Yorktown.
Although VFA and Gillman are joining in this Schedule as Reporting Persons, the filing of this
Schedule shall not be construed as an admission that either of them is, for any purpose, the
beneficial owner of the Common Stock held by Boston and Yorktown. Similarly, Boston and Yorktown
disclaim beneficial ownership of the shares held directly by the other.
c) Since the Reporting Persons’ most recent filing of Schedule 13D, Boston and Yorktown have
conducted the following transactions in the Common Stock in the open market:
Boston:
| |
|
|
|
|
|
|
|
|
| |
|
Quantity |
|
|
| |
|
Bought or |
|
|
| Trade Date |
|
(Sold) |
|
Price Per Share |
6/1/07 |
|
|
1,900 |
|
|
|
1.04 |
|
| |
|
|
|
|
|
|
|
|
|
|
CUSIP NO. |
|
279445886 |
SCHEDULE 13D |
Yorktown:
| |
|
|
|
|
|
|
|
|
| |
|
Quantity |
|
|
| |
|
Bought or |
|
|
| Trade Date |
|
(Sold) |
|
Price Per Share |
5/17/07 |
|
|
20,894 |
|
|
$ |
1.02 |
|
5/22/07 |
|
|
7,466 |
|
|
|
1.08 |
|
5/29/07 |
|
|
11,740 |
|
|
|
1.05 |
|
6/28/07 |
|
|
10,758 |
|
|
|
1.08 |
|
6/29/07 |
|
|
3,179 |
|
|
|
1.09 |
|
7/2/07 |
|
|
556 |
|
|
|
1.13 |
|
7/3/07 |
|
|
1,100 |
|
|
|
1.11 |
|
7/5/07 |
|
|
3,729 |
|
|
|
1.11 |
|
7/6/07 |
|
|
5,343 |
|
|
$ |
1.08 |
|
7/10/07 |
|
|
5,466 |
|
|
$ |
1.10 |
|
7/11/07 |
|
|
12,300 |
|
|
$ |
1.15 |
|
7/16/07 |
|
|
3,509 |
|
|
$ |
1.11 |
|
7/17/07 |
|
|
7,800 |
|
|
$ |
1.15 |
|
7/19/07 |
|
|
24,726 |
|
|
$ |
1.12 |
|
7/24/07 |
|
|
(4,000 |
) |
|
$ |
1.05 |
|
(d) and (e) Not applicable.
Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the
Issuer
None of the Reporting Persons is a party to any contract, arrangement, understanding or
relationship with respect to any securities of the Issuer.
Item 7. Material to be Filed as Exhibits
Exhibit A Joint Filing Undertaking.
| |
|
|
|
|
|
|
|
|
|
|
CUSIP NO. |
|
279445886 |
SCHEDULE 13D |
SIGNATURES
After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that
the information set forth in this statement is true, complete and correct.
Dated: July 27, 2007
| |
|
|
|
|
| |
Value Fund Advisors, LLC
|
|
| |
By: |
/s/ Charles M. Gillman
|
|
| |
|
Charles M. Gillman, Manager |
|
| |
|
|
|
| |
| |
Boston Avenue Capital, LLC
|
|
| |
By: |
/s/ Charles M. Gillman
|
|
| |
|
Charles M. Gillman, Manager |
|
| |
|
|
|
| |
| |
Yorktown Avenue Capital, LLC
|
|
| |
By: |
/s/ Charles M. Gillman
|
|
| |
|
Charles M. Gillman, Manager |
|
| |
|
|
|
| |
| |
|
|
| |
/s/ Charles M. Gillman
|
|
| |
Charles M. Gillman |
|
| |
|
|